its run too hard, page-14

Its all about the bigger picture. So far the management & research team have put in the hard yards to meet the necessary hurdles going fwd.

IMHO, PRR is moving up on its own merits, pls chk out their presentations & mkt updates.

And most imp. for us, each day DNDN gets closer to its FDA application in Nov, is another notch on the calendar. DNDN took a hit small hit after its analyst preso late Sept, simply b'coz profit takers moved in!!

Little did they realise that the plant is in place for now, but commercialising agreements for domestic & international mkts etc takes time, so the push to production by mid-2010 meant a 6 month production/sales window, instead of a full 12 months. Imagine the likes of GSK or Pfizer etc mkt'ing their product & CVAC in time globally. No wonder MR thinks there's a mkt worth US$3.6b. I'd b happy with 20-30% of that.

PRR's SP has moved from 7c to 21.5c, so thats a triple bagger, isn't it. So more the local press writes about the facts, the better the publicity for the vaccine.

Its good that they've got Prof Ian Frazer onboard & the tie-up with Fred Hutchison Institute in Seattle where the hard yards are being put in, otherwise most would have labelled it as just another vaccine trial !!

PRR will run on its own merit.